Liquid biopsy-based biomarkers for the characterization of hormone receptor-positive (HR+) HER2-Low metastatic breast cancer (mBC)

被引：0
|
作者：
Bortot, L. [1 ]
Basile, D. [2 ]
Palmero, L. [1 ]
Dri, A. [1 ]
Cucciniello, L. [1 ]
Buriolla, S. [1 ]
Pasto, B. [1 ]
Mazzeo, R. [1 ]
Bonotto, M. [3 ]
Bolzonello, S. [4 ]
Franzoni, A. [5 ]
Allegri, L. [5 ]
Belletti, B. [6 ]
Damante, G. [1 ]
Gerratana, L. [7 ]
Minisini, A. M. M. [3 ]
Puglisi, F. [8 ,9 ]
机构：
[1] Univ Udine, Dept Med DAME, Udine, Italy
[2] San Giovanni Dio Hosp, Med Oncol Unit, Crotone, Italy
[3] Azienda Sanitaria Univ Friuli Cent ASUFC, Santa Maria Misericordia Acad Hosp, Dept Oncol, Udine, Italy
[4] Ctr Riferimento Oncologico CRO, Dept Med Oncol, IRCCS, Aviano, Italy
[5] Azienda Sanitaria Univ Friuli Centrale ASUFC, Inst Human Genet, Udine, Italy
[6] Ctr Riferimento Oncol Aviano CRO, Mol Oncol Unit, IRCCS, Aviano, Italy
[7] Ctr Riferimento Oncol CRO, Dept Med Oncol, IRCCS, Aviano, Italy
[8] Univ Udine, Dept Med DAME, Udine, Italy
[9] Univ Udine, Dept Med DAME, Pordenone, Italy
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.300
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
261P
引用
收藏
页码：S656 / S657
页数：2
相关论文
共 50 条
  • [41] Circulating tumor DNA (ctDNA) mutation (mut) profile in relation to paboclicib (pal) efficacy in hormone receptor positive (HR+) and HER2 negative (HER2-) metastatic breast cancer (MBC)
    Xi, Jing
    Bagegni, Nusayba
    Ademuyiwa, Foluso
    Frith, Ashley
    Suresh, Rama
    Roshal, Anna
    Rigden, Caron
    Hernandez-Aya, Leonel
    Peterson, Lindsay
    Opyrchal, Mateusz
    Clifton, Katherine
    Weilbaecher, Katherine
    Bose, Ron
    Ma, Cynthia
    CANCER RESEARCH, 2021, 81 (04)
  • [42] Disease features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients
    Wang, Jinhao
    Liu, Yaxin
    Shao, Bin
    Dong, Hang
    Zheng, Tiantian
    Du, Pan
    Jia, Shidong
    King, Bonnie
    Wang, Jing
    Liu, Xiaoran
    Li, Huiping
    CANCER RESEARCH, 2023, 83 (05)
  • [43] Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+advanced or metastatic breast cancer(MBC)
    Riemsma, Rob
    Forbes, Carol A.
    Amonkar, Mayur M.
    Lykopoulos, Konstantinos
    Diaz, Jose R.
    Kleijnen, Jos
    Rea, Daniel W.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (08) : 1263 - 1279
  • [44] Liquid biopsy-based technologies: a promising tool for biomarker identification in her2-low breast cancer patients for improved therapeutic outcomes
    d'Alessandro, Aldo
    Deaconu, Anca Florentina
    Mandolesi, Sandro
    Fabrizio, Federico Pio
    Lombardi, Massimo
    Liguori, Giovanna
    Pepe, Giovanni
    Marino, Nicola
    Stingi, Aureliano
    d'Alessandro, Alessandro
    Giordano, Antonio
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2024, 10
  • [45] Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
    Wang, Jinhao
    Liu, Yaxin
    Liang, Yuehua
    Zhang, Yue
    Dong, Hang
    Zheng, Tiantian
    Yu, Jianjun
    Du, Pan
    Jia, Shidong
    King, Bonnie L. L.
    Wang, Jing
    Liu, Xiaoran
    Li, Huiping
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [46] Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer
    You, Shuhui
    Gong, Chengcheng
    Li, Yi
    Xie, Yizhao
    Li, Yumeng
    Zhao, Yannan
    Wang, Biyun
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [47] Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Lim, Joline Si Jing
    Wong, Andrea
    Ow, Samuel Guan Wei
    Ngoi, Natalie
    Ang, Yvonne Li'en
    Chan, Gloria
    Eng, Lim Siew
    Chong, Wan Qin
    Choo, Joan
    Lee, Matilda
    Tan, Hon Lyn
    Jan, Yi-hua
    Tan, Kien Thiam
    Sundar, Raghav
    Tan, David Shao Peng
    Soo, Ross A.
    Chee, Cheng Ean
    Yong, Wei-Peng
    Goh, Boon C.
    Lee, Soo-Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Treatment of HER2-positive (HER2+) hormone-receptor positive (HR plus ) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant
    Escriva-De-Romani, Santiago
    Alba, Emilio
    Rodriguez-Lescure, Alvaro
    Hurvitz, Sara
    Cejalvo, Juan Miguel
    Gion, Maria
    Ferrario, Cristiano
    Borrego, Manuel Ruiz
    Pezo, Rossanna C.
    Hamilton, Erika
    Webster, Marc
    Pluard, Timothy
    Beeram, Muralidhar
    Rodriguez, Begona Jimenez
    Linden, Hannah
    Saura, Cristina
    Omidpanah, Adam
    Harvey, Phoebe
    Savard, Marie-France
    CANCER RESEARCH, 2023, 83 (05)
  • [49] Breast cancer specific survival (BCSS) in HR+/HER2-metastatic breast cancer (mBC) from 2010 to 2019
    Brufsky, A. M.
    Kwan, M.
    Sandin, R.
    Karanth, S.
    Cha-Silva, A.
    Makari, D.
    Stergiopoulos, S.
    Goyal, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S351 - S352
  • [50] Prognostic impact of HER2-low expression according to the oncotype Dx recurrence score in hormone receptor-positive early breast cancer
    Mutai, R.
    Barkan, T.
    Moore, A.
    Sarfaty, M.
    Stemmer, S.
    Shohat, T.
    Yerushlami, R.
    Goldvaser, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S424 - S424
12345